Indication

For the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Upadacitinib may be used as monotherapy or in combination with methotrexate

Medicine details

Medicine name:
upadacitinb (Rinvoq)
SMC ID:
SMC2361
Pharmaceutical company
AbbVie Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Abbreviated
Publication due date:
10 May 2021